<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-165065" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Silver Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Steck</surname>
            <given-names>Matthew B.</given-names>
          </name>
          <aff>Michigan State University College of Osteopathic Medicine, McLaren Macomb Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Murray</surname>
            <given-names>Brian P.</given-names>
          </name>
          <aff>Wright State University Boonshoft School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Steck declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Murray declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-165065.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Silver is a soft metal that is not&#x000a0;essential for biological processes. This metal has the best electrical and thermal conductivity and reflectivity compared to all other metals.<xref ref-type="bibr" rid="article-165065.r1">[1]</xref>&#x000a0;These properties&#x000a0;provide a wide variety of uses and applications in society. Human exposure to silver has occurred for centuries, dating back to ancient civilizations. Exposures to silver occur through industry, occupational exposure, medications, and health and nutritional supplements. Repeated or prolonged exposure to silver can lead to silver toxicity, with the most common health effect being irreversibly localized and generalized blue to slate-gray skin pigmentation secondary to silver deposition called argyria.<xref ref-type="bibr" rid="article-165065.r2">[2]</xref>&#x000a0;The amount of silver in human tissues is low. However, overexposure can result in the accumulation of silver in the skin, liver, kidneys, mucous membranes, corneas, gingiva, spleen, and nails.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref></p>
      </sec>
      <sec id="article-165065.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>Exposure to silver can occur through various mechanisms, including ingestion, inhalation, and dermal exposure.<xref ref-type="bibr" rid="article-165065.r1">[1]</xref><xref ref-type="bibr" rid="article-165065.r4">[4]</xref></p>
        <p>
<bold>Common Products&#x000a0;Containing Silver</bold>
</p>
        <p>Silver compounds can be found in different products. A review by Drake and Hazelwood in 2005 listed numerous uses of silver compounds, including, but not limited to, photographic plates, batteries, bactericides, catalysts, medicinals, lubrications, cloud seeding, window coatings, mirrors, flower preservatives, electroplating, sanitation products, and acupuncture needles. In the same review, products containing silver and silver alloys include jewelry, silverware, electronic components, heat sinks, solders, brazing alloys, superconductors, bactericides, dental fillings, bearings, coins, and medals.</p>
        <p>
<bold>Occupational&#x000a0;Exposure</bold>
</p>
        <p>Occupational exposure can be associated with repeated exposure to small silver particles.&#x000a0;Professions at risk include silversmiths, miners, welders, jewelers, and those in the photographic industry. Occupational exposure limits can vary by organization. The European Commission recommends an 8-hour time-weighted average of 0.1 mg/m&#x000b3; for total silver dust. Other European countries have set separate recommended exposure levels of 0.1 mg/m&#x000b3; for metallic silver and 0.01 mg/m&#x000b3; for soluble silver. The Occupational Safety and Health Administration and the Mine Safety and Health Administration recognize a Permissible Exposure Limit of 0.01&#x000a0;mg/m&#x000b3;. Similarly, the National Institute for Occupational Safety and Health has a recommended exposure limit&#x000a0;of the same value for metallic and soluble silver.</p>
        <p>
<bold>Medical&#x000a0;Uses</bold>
</p>
        <p>Medical uses of silver include silver nitrate for cauterization and silver sulfadiazine for the topical treatment of burns and wounds. Minute levels of silver cations have microbicidal properties that are effective in wound and burn treatment. Medical device catheters are also layered with silver to prevent microbial growth.<xref ref-type="bibr" rid="article-165065.r5">[5]</xref>&#x000a0;The antimicrobial property of silver is hypothesized to be related to the ability of silver ions to combine with and permanently damage bacterial membranes.<xref ref-type="bibr" rid="article-165065.r6">[6]</xref></p>
        <p>
<bold>Consumer&#x000a0;Uses</bold>
</p>
        <p>Due to the proposed oligodynamic effect, consumer use includes colloidal silver as an over-the-counter dietary and health supplement in alternative and homeopathic medicine. Silver has also been utilized in grooming and hygiene products, such as bandages, shower gels, and deodorants.<xref ref-type="bibr" rid="article-165065.r7">[7]</xref>&#x000a0;The 1994 Dietary Supplement Health and Education Act allows silver to be sold as a supplement as long as no claim of treatment or prevention of any disease is apparent.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref></p>
        <p>The most common adverse effects linked to silver are argyria, irreversible bluish-gray skin pigmentation, and argyrosis, irreversible pigmentation of the eyes.&#x000a0;These effects are most noticeable in areas that are exposed to sunlight.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;Argyria is typically associated with prolonged exposure to silver, including applying silver-containing materials to the skin or body, inhalation in occupational settings, ingestion, and use of colloidal silver and silver-containing medicinals, smoking deterrents, dental materials, and silver solder.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref>&#x000a0;The toxicity of silver nanoparticles in different organs is hypothesized to be due to the same proposed mechanisms of the antimicrobial effects of silver nanoparticles&#x02014;vigorous oxidation due to ample discharge of silver ions.<xref ref-type="bibr" rid="article-165065.r10">[10]</xref></p>
      </sec>
      <sec id="article-165065.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Silver has been used dating back to ancient civilizations. The discovery and development of antibiotics in the early to mid-20th century led to a decline in the use of silver as an antimicrobial agent. Although rare, cases of argyria still occur. These instances are generally associated with consuming colloidal silver as a form of alternative and homeopathic medicine&#x000a0;as readily available in pharmacies, grocery stores, and online.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;Recent&#x000a0;re-emergence&#x000a0;in cases of argyria&#x000a0;has occurred due to these alternative health&#x000a0;treatment&#x000a0;trends.<xref ref-type="bibr" rid="article-165065.r11">[11]</xref>&#x000a0;The 1994 Dietary Supplement Health and Education Act allowed silver to be sold as a supplement as long as no claim of treatment or prevention of any disease was apparent.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;In 1999, the&#x000a0;United States Food and Drug Administration issued a final rule that all over-the-counter drug products containing colloidal silver ingredients or silver salts for internal or external use are not generally recognized as safe and effective and are misbranded.<xref ref-type="bibr" rid="article-165065.r12">[12]</xref></p>
        <p>Recently, there has been an increase in the use of ionic and nanoparticulate silver in medical and commercial products.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref>&#x000a0;Colloidal silver comprises silver particles and ions less than 100 nm (nanoparticles) and less than 1000 nm (microparticles) in size dispersed in an aqueous suspension.&#x000a0;Most products containing colloidal on the market are claimed to contain 10 to 30 mg/L of silver. The World Health Organization (WHO) has given a Reference Dose (RfD) of 6.5 mcg/kg body weight/day for all exposure routes for the general population, based on argyria development, which is not the most sensitive toxicity endpoint.<xref ref-type="bibr" rid="article-165065.r10">[10]</xref></p>
        <p>The mass production and subsequent commercialization of colloidal silver have adverse effects, including&#x000a0;a lack of production standardization&#x000a0;and unanticipated adverse effects. Regulatory bodies such as the Food and Drug Administration and the European Commission have taken a stance against health claims without scientific basis.&#x000a0;Although&#x000a0;they do not prohibit selling colloidal silver, unsubstantiated health claims are prohibited.<xref ref-type="bibr" rid="article-165065.r7">[7]</xref></p>
      </sec>
      <sec id="article-165065.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The complications of silver toxicity include dermatologic, cardiovascular, hematologic, hepatic, gastrointestinal, neurologic, and renal findings.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;The most common manifestation of excessive silver exposure is argyria, a condition characterized by&#x000a0;bluish-gray skin discoloration. Argyria can be generalized, localized, or ocular.&#x000a0;However,&#x000a0;more severe manifestations of silver toxicity have been demonstrated. In a large enough dose, silver is acutely toxic. An intravenous dose of about 50 mg of silver is considered fatal, leading&#x000a0;to bone marrow, renal, and hepatic necrosis, hemorrhage, and pulmonary edema.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;Although silver is not considered carcinogenic, genotoxic effects have been reported. There are no known effective chelators for treating silver toxicity.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref></p>
        <p>Although the exact antimicrobial mechanism of silver is unknown,&#x000a0;the proposed mechanisms include induction of oxidative stress, interaction with cellular membranes, and inhibition of cellular processes.<xref ref-type="bibr" rid="article-165065.r5">[5]</xref><xref ref-type="bibr" rid="article-165065.r6">[6]</xref>&#x000a0;Silver has various oxidation states, including Ag<sup>+</sup>, Ag<sup>2+</sup>, and Ag<sup>3+</sup>, with Ag<sup>+</sup>&#x000a0;being&#x000a0;the most biologically active oxidation state.&#x000a0;Silver induces&#x000a0;reactive oxygen species by inactivating the respiratory chain dehydrogenase.&#x000a0;This inactivation blocks the respiratory chain electron transfer, leading to decreased ATP production by inhibiting cellular respiration and growth.&#x000a0;Oxidative stress plays an important role in the cytotoxicity of silver, leading to inflammation and apoptosis.<xref ref-type="bibr" rid="article-165065.r13">[13]</xref></p>
        <p>Silver's&#x000a0;proposed activity is related to silver ion interactions with thiol groups in enzymes by&#x000a0;binding to electron donor groups of proteins, inhibiting enzymatic activities and causing&#x000a0;protein denaturation and precipitation.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;This process can occur by destroying the cell wall and membrane, increasing the cytoplasmic membrane's permeability and causing the destruction of the bacterial envelope. Silver nanoparticles transport&#x000a0;silver ions to bacterial cells, reducing pH and increasing silver ion release.<xref ref-type="bibr" rid="article-165065.r14">[14]</xref>&#x000a0;In addition, silver binding to DNA affects the replication of DNA and cell proliferation.<xref ref-type="bibr" rid="article-165065.r15">[15]</xref>&#x000a0;Silver disrupts sodium-potassium-ATPase&#x000a0;by interacting with sulfhydryl groups, causing rapid and potent enzymatic inhibition.<xref ref-type="bibr" rid="article-165065.r16">[16]</xref></p>
      </sec>
      <sec id="article-165065.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Silver particles have a dark brown to black granular appearance. In the dermis, they are scattered extracellularly and are concentrated in the basement membrane of nerves, capillary walls, perifollicular sheath, and elastic fibers.&#x000a0;In old lesions, electron-dense granules are observed in lysosomes of macrophages or extracellularly using scanning electron microscopy.<xref ref-type="bibr" rid="article-165065.r17">[17]</xref></p>
      </sec>
      <sec id="article-165065.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>
<bold>Absorption</bold>
</p>
        <p>The absorption of silver can occur through multiple modalities, including inhalation, oral ingestion, or skin contact. The rate of silver absorption depends on both the route of exposure and the form of silver. Specifically, particle size plays a role as smaller nanoparticles are more easily absorbed into the bloodstream, possibly leading to systemic exposure. An in vivo study using radiolabeled silver showed accumulation after 2 to 8 hours of exposure, with clearance within 28 days. Oral absorption through the gastrointestinal tract can vary based on other dietary components potentially affecting silver's bioavailability.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;The estimated absorption of ingested silver is up to 10%.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref>&#x000a0;Dermal exposure can be affected by prolonged exposure and exposure to areas of skin breakdown, which is important for specific medical devices and dressings.</p>
        <p>
<bold>Distribution</bold>
</p>
        <p>After silver is absorbed, it is distributed through the bloodstream, binding to plasma proteins and transporting them to various organs and tissues. Detectable levels of silver were reported in the blood within 6 hours and in the urine within 24 hours after the application of silver sulfadiazine. Silver binds with sulfur-containing molecules, accumulating in the skin, hair, and nails. Silver can cross the blood-brain and placental barriers.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Silver metabolism is limited in the body. However, interaction with other molecules can lead to biotransformation, which affects its bioavailability.<xref ref-type="bibr" rid="article-165065.r6">[6]</xref><xref ref-type="bibr" rid="article-165065.r18">[18]</xref>&#x000a0;The biological half-life of silver in the liver is 50 days.</p>
        <p>
<bold>Excretion</bold>
</p>
        <p>Silver is primarily excreted through the feces by biliary secretion and is also excreted through the urine in smaller quantities. The mean urinary excretion of silver was approximately 1100 &#x000b5;g/L compared to levels of less than 1 &#x000b5;g/L in control levels. The elimination of silver is estimated&#x000a0;at 46.4 days from serum, with a median elimination rate of 1.5% per day.<xref ref-type="bibr" rid="article-165065.r19">[19]</xref> The efficiency of urinary excretion is impacted by renal clearance.<xref ref-type="bibr" rid="article-165065.r20">[20]</xref> Additional routes of excretion include sweat, saliva, and breast milk.<xref ref-type="bibr" rid="article-165065.r6">[6]</xref></p>
      </sec>
      <sec id="article-165065.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A medical diagnosis of silver toxicity requires a high level of clinical suspicion,&#x000a0;often accompanied by a history of silver exposure through occupational, medicinal, or consumer exposures. An emphasis on obtaining an extended history of over-the-counter, natural, alternative, or homeopathic supplements may heighten clinical suspicion. The onset of pigmentation can vary widely, ranging from days to years. Given that the deposition is permanent, the diagnosis of argyria can be made regardless of the time that has passed since the initial exposure.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref></p>
        <p>Physical examination findings include localized and generalized blue to slate-gray skin pigmentation secondary to silver deposition.<xref ref-type="bibr" rid="article-165065.r2">[2]</xref>&#x000a0;Generalized argyria progresses in stages, beginning with staining of the gingiva,&#x000a0;followed by hyperpigmentation in sun-exposed areas, and then affecting the nail beds, sclerae, and mucosa. In addition, viscera are noted to appear blue on autopsy. Sun-exposed areas are typically darker secondary to sunlight, leading to a decrease&#x000a0;in elemental silver and causing a darker pigmented discoloration.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref><xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;The photoactivation of sun-exposed areas reduces silver, which accelerates the stimulation of melanocytes by silver to increase melanin production.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;The increased production can be observed in the skin, nails, eyes, and mucosal surfaces.</p>
      </sec>
      <sec id="article-165065.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The normal value of silver in blood is less than 1 mcg/L.&#x000a0;Silver can be measured in the blood, feces, and urine.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref>&#x000a0;The lowest level for silver buildup to result in generalized argyria varies considerably, and thus, argyria is typically diagnosed through history and physical exams.&#x000a0;No minimum serum silver levels are consistent with early argyria.<xref ref-type="bibr" rid="article-165065.r18">[18]</xref>&#x000a0;Estimated cumulative doses leading to generalized argyria in humans have been reported as low as 70 mg/kg body weight.<xref ref-type="bibr" rid="article-165065.r13">[13]</xref> A skin biopsy and histopathological analysis are useful, with the gold standard being energy-dispersive x-ray spectroscopy.&#x000a0;This&#x000a0;technique&#x000a0;allows for unequivocal diagnosis&#x000a0;by identification of the chemical elements found in the granules through analysis of their emitted energy spectrum.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref><xref ref-type="bibr" rid="article-165065.r9">[9]</xref></p>
      </sec>
      <sec id="article-165065.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>There is no specific antidote available to silver toxicity, and treatment of toxicity is supportive.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;The treatment for argyria is limited with overall poor response and is historically considered permanent. A&#x000a0;major focus of management&#x000a0;is to limit exacerbating factors, such as avoiding further exposure to silver, limiting sun exposure, and utilizing sun protection.<xref ref-type="bibr" rid="article-165065.r21">[21]</xref>&#x000a0;Potential treatments with hydroquinone, dermabrasions, and D-penicillamine have been attempted without notable results.</p>
        <p>In recent reports, Q-switched frequency neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy, which is used for removing certain tattoos, has also been attempted with documentation of successful improvement of discoloration after treatments with low-fluence Q-switched 1064-nm Nd:YAG laser and 755-nm alexandrite laser.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref><xref ref-type="bibr" rid="article-165065.r22">[22]</xref><xref ref-type="bibr" rid="article-165065.r23">[23]</xref>&#x000a0;Persistent skin color restoration up to&#x000a0;1 year after treatment has been reported; however, argyria relapse 11 months after has also been reported. Adverse effects of the laser procedure include intense pain, which may require various types of anesthesia, including general anesthesia.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref></p>
      </sec>
      <sec id="article-165065.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis of silver toxicity includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Addison disease</p>
          </list-item>
          <list-item>
            <p>Amiodarone use</p>
          </list-item>
          <list-item>
            <p>Chrysiasis</p>
          </list-item>
          <list-item>
            <p>Cyanosis</p>
          </list-item>
          <list-item>
            <p>Dapsone use</p>
          </list-item>
          <list-item>
            <p>Hemochromatosis</p>
          </list-item>
          <list-item>
            <p>Melanoma</p>
          </list-item>
          <list-item>
            <p>Methemoglobinemia</p>
          </list-item>
          <list-item>
            <p>Minocycline use</p>
          </list-item>
          <list-item>
            <p>Ochronosis</p>
          </list-item>
          <list-item>
            <p>Phenothiazine use</p>
          </list-item>
          <list-item>
            <p>Polycythemia</p>
          </list-item>
          <list-item>
            <p>Porphyria</p>
          </list-item>
          <list-item>
            <p>Wilson disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-165065.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>When silver is ingested, approximately 10% is absorbed in the gastrointestinal tract and circulated by the vasculature. Silver is primarily excreted in bile and eliminated through feces, and to a lesser extent, eliminated in urine.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref><xref ref-type="bibr" rid="article-165065.r8">[8]</xref>&#x000a0;In today&#x02019;s society, presentations of generalized argyria are most commonly&#x000a0;observed in patients who utilize colloidal silver as a form of complementary health supplementation.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;Inhaling silver particulates or aerosols leads to the accumulation of silver in the lungs and bloodstream.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref><xref ref-type="bibr" rid="article-165065.r20">[20]</xref>&#x000a0;The Recommended Exposure Level and Permissible Exposure Level for both are 0.1 mg/m<sup>3</sup>, according to the National Institute of Occupational Safety and Health established by the Occupational Health and Safety Administration. Contact exposure to silver can occur through wound dressings, jewelry, and nasal or ophthalmologic drops, typically leading to localized argyria. However, contact exposure can still lead to generalized argyria.<xref ref-type="bibr" rid="article-165065.r2">[2]</xref><xref ref-type="bibr" rid="article-165065.r13">[13]</xref></p>
      </sec>
      <sec id="article-165065.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Argyria is mainly irreversible and does not improve after discontinuation of exposure. Argyria is not a life-threatening condition; however,&#x000a0;the metal demonstrates systemic absorption and distribution of silver, leading to an unfavorable cosmetic appearance with permanent skin discoloration in the affected areas.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;The highest concentrations of silver are found in the skin, liver, kidneys, cornea, and gingiva, as indicated by autopsy analysis of individuals treated with silver for burns.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref></p>
      </sec>
      <sec id="article-165065.s13" sec-type="Complications">
        <title>Complications</title>
        <p>
<bold>Systemic&#x000a0;Complications</bold>
</p>
        <p>Systemic complications of silver toxicity have been described in the literature in the form of animal studies and case reports. Silver has been demonstrated to accumulate throughout the body in animal research.&#x000a0;Systemic complications include cardiovascular, dermatologic, hematologic, hepatic, gastrointestinal, neurologic, and renal findings.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref><xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;</p>
        <p><bold>Dermatologic:&#x000a0;</bold>Argyria, the development of bluish-gray skin discoloration, is the most well-known complication of silver exposure. There are&#x000a0;3 main subtypes of argyria&#x02014;generalized argyria, localized argyria, and argyrosis.&#x000a0;Generalized argyria occurs after systemic exposure, resulting in gray-blue or metallic diffuse skin pigmentation, most prominent in sun-exposed areas.&#x000a0;Early signs include pigmentation of the gingiva and oral mucosa followed by bluish discoloration of the fingernails called azure lunula. Localized argyria is caused by local silver deposition due to transdermal absorption by sweat gland pores or skin incisions.&#x000a0;This condition is observed after prolonged contact with silver-containing products, creams, solutions, or cautery. The most common form of localized argyria is amalgam tattoo, a&#x000a0;flat, dark-blue mucosal lesion. Argyrosis is an ocular silver deposition that can occur as a manifestation of generalized or localized argyria.&#x000a0;Argyrosis can be&#x000a0;observed in the cornea, conjunctivae, and lacrimal caruncle and may have dark lesions with greenish and brownish tones.<xref ref-type="bibr" rid="article-165065.r4">[4]</xref>&#x000a0;</p>
        <p><bold>Neurologic:&#x000a0;</bold>Neurologic complications include accumulation of silver in neuron and glial cells of the brain and spinal cord, potential&#x000a0;central nervous system dysfunction in mice exposed to silver salts, and a decrease in emergent hippocampal pyramidal cells in fetal rats. In addition, a report described a 55-year-old woman who experienced increasing vertigo, weakness, hyposmia, gait disturbance, and cutaneous hypoesthesia after self-treating oral mycosis&#x000a0;with&#x000a0;silver products for&#x000a0;9 years.&#x000a0;This prolonged use of silver products led to silver sulfide depositions found in basal membranes, macrophages, elastic and collagenous fibers, perineurium of peripheral nerves, and necrotic cells of the oral submucosa. A case reported by Ohbo et al suggests a causal relationship of convulsive seizures in a patient with schizophrenia with argyria secondary to addiction to antismoking pills containing silver with serum levels of 12 mcg/L.<xref ref-type="bibr" rid="article-165065.r24">[24]</xref></p>
        <p><bold>Renal:&#x000a0;</bold>Reported renal findings include proteinuria and damaged glomeruli in other cases.&#x000a0;A patient developed chronic abdominal pain after using topical silver for&#x000a0;2 and a half years to help with recurrent gingival bleeding, which led to generalized argyria. The patient underwent an abdominal operation, during which diffuse argyria of multiple internal organs was observed.</p>
        <p><bold>Hematologic:&#x000a0;</bold>In the bone marrow, silver sulfadiazine use has been shown to suppress leukocyte progenitor cells in mice studies,&#x000a0;along with leukopenia and lowered granulocyte counts in patients with burn wounds.<xref ref-type="bibr" rid="article-165065.r18">[18]</xref>&#x000a0;</p>
        <p><bold>Hepatic: </bold>Rats deficient in vitamin E or selenium developed hepatic necrosis due to selenium deficiency caused by silver,&#x000a0;which obstructed the production of the seleno-enzyme glutathione peroxidase.</p>
        <p><bold>Cardiovascular:&#x000a0;</bold>In&#x000a0;a case report by Steininger et al, a 52-year-old patient who died from cardiac failure was found to have silver deposits in the walls of most blood vessels on autopsy. This patient was treated&#x000a0;for a duodenal ulcer for over 18 years with 35 g of silver.&#x000a0;In a study by Olcott, rats given silver nitrate drinking water developed left ventricular&#x000a0;enlargement. [ATSDR. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.atsdr.cdc.gov/ToxProfiles/tp146.pdf">Toxicological Profile for Silver</ext-link>]</p>
        <p><bold>Respiratory:&#x000a0;</bold>Inhalation of silver can lead to pneumonitis, with reports of both upper and lower respiratory irritation.&#x000a0;Tracheal epithelium structural damage was&#x000a0;observed&#x000a0;in rabbits who experienced inhalation exposure to colloidal silver. A case report by Forycki et al described a man hospitalized approximately 36 hours after exposure to silver vapors from melting silver ingots, presenting with&#x000a0;severe circulatory and respiratory symptoms requiring controlled respiration with positive end-expiratory pressure.<xref ref-type="bibr" rid="article-165065.r3">[3]</xref><xref ref-type="bibr" rid="article-165065.r25">[25]</xref></p>
        <p>
<bold>Fatal Dose</bold>
</p>
        <p>The reported fatal dose of intravenous colloidal silver is 50 mg acutely, leading to bone marrow, renal, and hepatic necrosis, hemorrhage, and pulmonary edema.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref>&#x000a0;Additional sources report an average fatal dose of 10 g, although survival after 30 g is also reported.<xref ref-type="bibr" rid="article-165065.r8">[8]</xref> The World Health Organization reports a lifetime intake of approximately 10 g of silver can be considered the no-observed<bold>-</bold>adverse-effect level in humans.<xref ref-type="bibr" rid="article-165065.r18">[18]</xref>&#x000a0;In a review by Fung et al, the systemic effects of silver are discussed.&#x000a0;Human mortality has been reported in the literature, including a case involving intrauterine silver nitrate administration of 7 g (approximately 64 mg silver/kg by weight) following an abortion procedure.<xref ref-type="bibr" rid="article-165065.r13">[13]</xref></p>
      </sec>
      <sec id="article-165065.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education regarding the risks and adverse effects of silver toxicity is crucial, including the potentially irreversible dermatologic effects of argyria. Improving awareness that government regulations of the commercial sales of colloidal silver occur with nonscientific-based claims of health benefits should also be noted.<xref ref-type="bibr" rid="article-165065.r7">[7]</xref><bold>&#x000a0;</bold>Psychological counseling and education regarding available treatment modalities are beneficial.<xref ref-type="bibr" rid="article-165065.r9">[9]</xref></p>
      </sec>
      <sec id="article-165065.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cases of silver toxicity are rare; however, they still occur in modern society. Clinicians must maintain a high clinical index of suspicion regarding obtaining pertinent history of silver exposure, including occupational history, medications, supplements, and alternative therapies to ensure an accurate&#x000a0;diagnosis. Careful consideration is warranted when excluding other pigmentation-based diagnoses.</p>
        <p>An interprofessional team is crucial for the diagnosis and management of silver toxicity. This team may include clinicians, toxicologists, dermatologists, and pathologists. Nurses play a vital role in this interprofessional team by coordinating the collection of blood and tissue specimens, assisting with patient examinations and history-taking, and counseling patients and their families regarding the condition and its management. This collaborative approach ensures comprehensive care and improves patient outcomes.</p>
      </sec>
      <sec id="article-165065.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=165065&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=165065">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/poisons/silver-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=165065">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/165065/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=165065">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-165065.s17">
        <title>References</title>
        <ref id="article-165065.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betts</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Whitehead</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Silver in biology and medicine: opportunities for metallomics researchers.</article-title>
            <source>Metallomics</source>
            <year>2021</year>
            <month>Jan</month>
            <day>16</day>
            <volume>13</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">33570135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffith</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Falto-Aizpurua</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Yazdani Abyaneh</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nouri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>1064&#x000a0;nm Q-switched Nd:YAG laser for the treatment of Argyria: a systematic review.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>11</issue>
            <fpage>2100</fpage>
            <page-range>2100-3</page-range>
            <pub-id pub-id-type="pmid">25845405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drake</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hazelwood</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Exposure-related health effects of silver and silver compounds: a review.</article-title>
            <source>Ann Occup Hyg</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>49</volume>
            <issue>7</issue>
            <fpage>575</fpage>
            <page-range>575-85</page-range>
            <pub-id pub-id-type="pmid">15964881</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mota</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dinis-Oliveira</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Forensic Aspects of the Different Subtypes of Argyria.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>May</month>
            <day>13</day>
            <volume>10</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">34068024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silver</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bacterial silver resistance: molecular biology and uses and misuses of silver compounds.</article-title>
            <source>FEMS Microbiol Rev</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>2-3</issue>
            <fpage>341</fpage>
            <page-range>341-53</page-range>
            <pub-id pub-id-type="pmid">12829274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lansdown</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Silver in health care: antimicrobial effects and safety in use.</article-title>
            <source>Curr Probl Dermatol</source>
            <year>2006</year>
            <volume>33</volume>
            <fpage>17</fpage>
            <page-range>17-34</page-range>
            <pub-id pub-id-type="pmid">16766878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sim</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Barnard</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Blaskovich</surname>
                <given-names>MAT</given-names>
              </name>
              <name>
                <surname>Ziora</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial Silver in Medicinal and Consumer Applications: A Patent Review of the Past Decade (2007&#x0207b;2017).</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2018</year>
            <month>Oct</month>
            <day>26</day>
            <volume>7</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30373130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fung</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Silver products for medical indications: risk-benefit assessment.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1996</year>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>119</fpage>
            <page-range>119-26</page-range>
            <pub-id pub-id-type="pmid">8632503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jerger</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <chapter-title>Argyria</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">33085270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leino</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Airaksinen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Viluksela</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>V&#x000e4;h&#x000e4;kangas</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of colloidal silver products and their marketing claims in Finland.</article-title>
            <source>Toxicol Rep</source>
            <year>2021</year>
            <volume>8</volume>
            <fpage>106</fpage>
            <page-range>106-113</page-range>
            <pub-id pub-id-type="pmid">33437653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Nagarajan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aung</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Ivan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Prieto</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Torres-Cabala</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Localized cutaneous argyria: Review of a rare clinical mimicker of melanocytic lesions.</article-title>
            <source>Ann Diagn Pathol</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>54</volume>
            <fpage>151776</fpage>
            <pub-id pub-id-type="pmid">34214703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <article-title>Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.</article-title>
            <source>Fed Regist</source>
            <year>1999</year>
            <month>Aug</month>
            <day>17</day>
            <volume>64</volume>
            <issue>158</issue>
            <fpage>44653</fpage>
            <page-range>44653-8</page-range>
            <pub-id pub-id-type="pmid">10558603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadrup</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Loeschner</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Toxicity of silver ions, metallic silver, and silver nanoparticle materials after in vivo dermal and mucosal surface exposure: A review.</article-title>
            <source>Regul Toxicol Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>98</volume>
            <fpage>257</fpage>
            <page-range>257-267</page-range>
            <pub-id pub-id-type="pmid">30125612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mikhailova</surname>
                <given-names>EO</given-names>
              </name>
            </person-group>
            <article-title>Silver Nanoparticles: Mechanism of Action and Probable Bio-Application.</article-title>
            <source>J Funct Biomater</source>
            <year>2020</year>
            <month>Nov</month>
            <day>26</day>
            <volume>11</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33255874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of bacterial resistance to environmental silver and antimicrobial strategies for silver: A review.</article-title>
            <source>Environ Res</source>
            <year>2024</year>
            <month>May</month>
            <day>01</day>
            <volume>248</volume>
            <fpage>118313</fpage>
            <pub-id pub-id-type="pmid">38280527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meneghini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moosmayer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lacotte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anner</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Potent and reversible interaction of silver with pure Na,K-ATPase and Na,K-ATPase-liposomes.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>1994</year>
            <month>Mar</month>
            <day>23</day>
            <volume>1190</volume>
            <issue>2</issue>
            <fpage>402</fpage>
            <page-range>402-8</page-range>
            <pub-id pub-id-type="pmid">8142442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Molina-Hernandez</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Diaz-Gonzalez</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Saeb-Lima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dominguez-Cherit</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Argyria after Silver Nitrate Intake: Case Report and Brief Review of Literature.</article-title>
            <source>Indian J Dermatol</source>
            <year>2015</year>
            <season>Sep-Oct</season>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>520</fpage>
            <pub-id pub-id-type="pmid">26538722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lansdown</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>A pharmacological and toxicological profile of silver as an antimicrobial agent in medical devices.</article-title>
            <source>Adv Pharmacol Sci</source>
            <year>2010</year>
            <volume>2010</volume>
            <fpage>910686</fpage>
            <pub-id pub-id-type="pmid">21188244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Parsons</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The biological fate of silver ions following the use of silver-containing wound care products - a review.</article-title>
            <source>Int Wound J</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>496</fpage>
            <page-range>496-504</page-range>
            <pub-id pub-id-type="pmid">23173975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiVincenzo</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Giordano</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schriever</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Biologic monitoring of workers exposed to silver.</article-title>
            <source>Int Arch Occup Environ Health</source>
            <year>1985</year>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>207</fpage>
            <page-range>207-15</page-range>
            <pub-id pub-id-type="pmid">4066049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Truitt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stetson</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Systemic argyria with severe anemia (hemoglobin 2.4&#x02009;g/L).</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2022</year>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-384</page-range>
            <pub-id pub-id-type="pmid">35518817</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Son</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of argyria using a low-fluence Q-switched 1064-nm Nd:YAG laser.</article-title>
            <source>Int J Dermatol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>751</fpage>
            <page-range>751-3</page-range>
            <pub-id pub-id-type="pmid">21595676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Almurayshid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Effective laser treatment options for argyria: Review of literatures.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>1877</fpage>
            <page-range>1877-1882</page-range>
            <pub-id pub-id-type="pmid">32538530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohbo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fukuzako</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takigawa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Argyria and convulsive seizures caused by ingestion of silver in a patient with schizophrenia.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>1996</year>
            <month>Apr</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-90</page-range>
            <pub-id pub-id-type="pmid">8783381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-165065.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Forycki</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zegarski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bardzik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swica</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Acute silver poisoning through inhalation.</article-title>
            <source>Bull Inst Marit Trop Med Gdynia</source>
            <year>1983</year>
            <volume>34</volume>
            <issue>3-4</issue>
            <fpage>199</fpage>
            <page-range>199-203</page-range>
            <pub-id pub-id-type="pmid">6681363</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
